News Release

An obesity treatment for women only?

Peer-Reviewed Publication

University of Virginia Health System

An obesity treatment for women only?

image: Mete Civelek, PhD, and his team have made a discovery that could open the door to a new treatment for obesity and type 2 diabetes in women. view more 

Credit: UVA Health

University of Virginia School of Medicine researchers have identified a potential way to battle the health effects of obesity and type 2 diabetes in women after discovering an important factor that could determine how their bodies use and store fat.

Based on their new discovery, the researchers, led by Associate Professor of Biomedical Engineering Mete Civelek, PhD, were able to change whether female lab mice’s bodies stored fat subcutaneously (under the skin) or viscerally (wrapped around the organs). While visceral fat goes unseen, hidden deep inside the body, it can be particularly harmful to good health.

The researchers say their results in mice suggest that a similar approach could help treat the effects of obesity and battle metabolic diseases, such as diabetes, in women.

“There is a strong need for targeted therapies against metabolic abnormalities caused by obesity and diabetes,” said the study’s first author, Qianyi Yang, PhD, of UVA’s Center for Public Health Genomics. “We hope that increasing KLF14 abundance in fat cells of females with obesity and diabetes may provide a novel treatment option to alleviate these metabolic abnormalities.”

How We Store Fat

Men and women naturally store fat differently. Men tend to be more apple-shaped, meaning they store fat around the waist, while women tend to be more pear-shaped. This is because women store more subcutaneous fat and less visceral fat in their lower body. Civelek’s new findings help explain why.

Civelek and his team were investigating a particular gene, KLF14, that has been linked to many different metabolic problems, including type 2 diabetes and coronary artery disease. These health associations are more pronounced in women than men, but scientists haven’t understood the reason.

Civelek and his collaborators found that the KLF14 gene is a key regulator of how the female body uses lipids (fats). The gene makes a protein that plays a critical in how fat cells form, what type of fat they turn into and where they are stored. When Civelek’s team blocked the production of this protein in lab mice, they noticed very different effects in males and females: Females gained fat, while males lost it. The females also stored fat differently than normal, gaining more visceral fat and less subcutaneous fat. 

There were other sex-specific changes as well: The female mice suffered slower metabolic rates and faster breathing, suggesting they were relying more on carbohydrates for fuel. And their bodies became less efficient at managing triglycerides, a type of fat in the blood.

Interestingly, when the researchers amped up production of the KLF14 protein in in female mice, the mice lost weight. But male mice did not. 

Based on what they’ve found, the researchers believe that increasing production of the KLF14 protein in fat cells in women may offer a way to treat the harmful effects of obesity and type 2 diabetes. More research will be needed, but the researchers say it is promising that their mouse findings align closely with what we see in humans.

“We are now working to create a drug delivery system that will target fat cells and deliver a small molecule to increase KLF14 abundance,” Civelek said. “We hope to translate our laboratory’s findings to the clinic to help women fight the effects of obesity and diabetes.”

Obesity Findings Published

The researchers have published their findings in the scientific journal Diabetes, a publication of the American Diabetes Association. The research team consisted of Yang, Jameson Hinkle, Jordan N. Reed, Redouane Aherrahrou, Zhiwen Xu, Thurl E. Harris, Erin J. Stephenson, Kiran Musunuru, Susanna R. Keller and Civelek. Musunuru is an adviser and holds equity in Verve Therapeutics and Variant Bio.

The work was supported by the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases, grant R01 DK118287, and the American Diabetes Association, grant 1-19-IBS-105.

UVA’s Department of Biomedical Engineering is a collaboration of UVA’s School of Medicine and School of Engineering.

To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.